![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g02.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
![JCI Insight - Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors JCI Insight - Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors](https://df6sxcketz7bb.cloudfront.net/manuscripts/92000/92352/medium/jci.insight.92352.f2.jpg)
JCI Insight - Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
![Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | Scientific Reports Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-07153-z/MediaObjects/41598_2022_7153_Fig1_HTML.png)
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | Scientific Reports
Mechanistic Understanding of Translational Pharmacokinetic- Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case St
![Tumor growth inhibition (TGI) and tumor-free animals in s.c. Z138 MCL... | Download Scientific Diagram Tumor growth inhibition (TGI) and tumor-free animals in s.c. Z138 MCL... | Download Scientific Diagram](https://www.researchgate.net/publication/259200320/figure/fig1/AS:297201055092736@1447869662025/Tumor-growth-inhibition-TGI-and-tumor-free-animals-in-sc-Z138-MCL-model-following-10.png)
Tumor growth inhibition (TGI) and tumor-free animals in s.c. Z138 MCL... | Download Scientific Diagram
A Platform for Rapid, Quantitative Assessment of Multiple Drug Combinations Simultaneously in Solid Tumors In Vivo | PLOS ONE
![Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram](https://www.researchgate.net/publication/324709939/figure/fig2/AS:618753171652608@1524533660275/Correlation-between-tumor-growth-inhibition-and-growth-rate-inhibition-for-xenograft_Q320.jpg)
Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram
![Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram](https://www.researchgate.net/publication/324709939/figure/fig1/AS:618753171664896@1524533660240/Commonly-used-antitumor-efficacy-metrics-Top-panel-T-C-ratio-Middle-panel-TGI-Bottom.png)
Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram
Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient–derived xenograft m
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g08.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
![Pharmaceutics | Free Full-Text | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice Pharmaceutics | Free Full-Text | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-12-00975/article_deploy/html/images/pharmaceutics-12-00975-g005.png?1603436374)
Pharmaceutics | Free Full-Text | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
Tumor growth inhibition (TGI)-monotherapy (a) and combination therapy (b). | Download Scientific Diagram
![Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2455-2/MediaObjects/12885_2016_2455_Fig1_HTML.gif)
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text
![Simulation Tumor Growth Profile of TGI Lifespan Model. Plot of tumor... | Download Scientific Diagram Simulation Tumor Growth Profile of TGI Lifespan Model. Plot of tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/267273025/figure/fig3/AS:295589012099074@1447485320193/Simulation-Tumor-Growth-Profile-of-TGI-Lifespan-Model-Plot-of-tumor-weight-vs-time-The.png)
Simulation Tumor Growth Profile of TGI Lifespan Model. Plot of tumor... | Download Scientific Diagram
![Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide | Oncogene Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide | Oncogene](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.onc.1205881/MediaObjects/41388_2002_Article_BF1205881_Fig1_HTML.jpg)
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide | Oncogene
![PK/TGI relationship for 23a in Karpas-422 xenograft model: (A) tumor... | Download Scientific Diagram PK/TGI relationship for 23a in Karpas-422 xenograft model: (A) tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/321627338/figure/fig5/AS:583107354824705@1516035035014/PK-TGI-relationship-for-23a-in-Karpas-422-xenograft-model-A-tumor-growth-inhibition.png)
PK/TGI relationship for 23a in Karpas-422 xenograft model: (A) tumor... | Download Scientific Diagram
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g06.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
![Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram](https://www.researchgate.net/publication/324709939/figure/fig1/AS:618753171664896@1524533660240/Commonly-used-antitumor-efficacy-metrics-Top-panel-T-C-ratio-Middle-panel-TGI-Bottom_Q640.jpg)